1,Product Name :ADC drug(Maytansinoids,Exatecans,MMAE/MMAFs)
2,Standard :In-house Standards
3,Grade :pharmaceutical grade
4,Factory Location :Suzhou Industrial Park, China
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Antibody-Drug Conjugates (ADCs) utilize potent cytotoxic payloads like <strong>Maytansinoids</strong>, <strong>Exatecans</strong>, and <strong>MMAE/MMAF</strong> linked to monoclonal antibodies. These highly specific agents deliver toxins directly to tumor cells, minimizing systemic exposure. Key linkers include disulfide bonds for MMAE and cleavable peptide linkers for stability.</p>
<h3>Application</h3>
<ul>
<li>Oncology: Targeted therapy for CD30+ lymphomas and HER2+ breast cancers.</li>
<li>Biopharmaceutical Manufacturing: GMP-grade synthesis of linker-payload intermediates.</li>
<li>Research: Preclinical development of novel antibody conjugates.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly handle as hazardous cytotoxins requiring PPE and containment. Store payloads at -20°C in desiccated conditions. Clinical use mandates monitoring for neutropenia and neuropathy due to off-target toxicity risks.</p>